Guideline | Organization | Published |
Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D) | European Consortium "Care for CMMR-D" (C4CMMR-D) | 2015 |
Referral indications for cancer predisposition assessment | American College of Medical Genetics and Genomics, National Society of Genetic Counselors | 2015 |
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines | American Society of Clinical Oncology,European Society for Medical Oncology | 2015 |
Genetic testing and management of individuals genetically at-risk of cutaneous melanoma | Expert group | 2015 |
Lynch syndrome: A primer for urologists and panel recommendations | Expert group | 2015 |
Updated UK Recommendations for HER2 assessment in breast cancer | National Coordinating Committee for Breast Pathology | 2015 |
Biomarker testing in colorectal carcinoma - update | Spanish Society of Pathology, Spanish Society of Medical Oncology | 2015 |
Endometrial cancer: a review and current management strategies: part I | Society of Gynecologic Oncology Clinical Practice Committee | 2014 |
Genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). | American College of Medical Genetics and Genomics | 2014 |
Collection and use of a cancer family health history for oncology providers | American Society of Clinical Oncology | 2014 |
Disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases | American Society of Clinical Oncology | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer | American Society of Clinical Oncology | 2014 |
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/Internat | American Society of Clinical Oncology | 2014 |
Human epidermal growth factor receptor 2 testing in breast cancer | American Society of Clinical Oncology,College of American Pathologists | 2014 |
RAS testing of colorectal carcinoma | Association of Clinical Pathologists Molecular Pathology and Diagnostics Group | 2014 |
Testing of ALK Gene Rearrangement in Lung Cancer | Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists | 2014 |
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers - 2014 update | European Group on Tumor Markers | 2014 |
Guidance for laboratories performing molecular pathology for cancer patients | European Society of Pathology Task Force on Quality Assurance in Molecular Pathology | 2014 |
Does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? | Evaluation of Genomic Applications in Practice and Prevention | 2014 |
Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era | Expert group | 2014 |
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years | International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee | 2014 |
Diagnosis and management of hereditary colorectal cancer - summarized from JSCCR Guidelines 2012 for the Clinical Practice of Hereditary Colorectal Cancer | Japanese Society for Cancer of the Colon and Rectum | 2014 |
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014 | National Comprehensive Cancer Network | 2014 |
Diagnosis, treatment and follow-up of hairy cell leukaemia | SFH (French Society of Haematology) | 2014 |
Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. | Spanish Society of Pathology, Spanish Society of Medical Oncology | 2014 |
Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations | US Food and Drug Administration | 2014 |
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation | US Food and Drug Administration | 2014 |
Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer | US Multi-society Task Force on colorectal cancer | 2014 |
Summaries for patients: assessing the genetic risk for BRCA-related breast or ovarian cancer in women | US Preventive Services Task Force | 2014 |
American College of Medical Genetics and Genomics technical standards and guidelines: Microarray analysis for chromosome abnormalities in neoplastic disorders | American College of Medical Genetics and Genomics | 2013 |
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. | American Society of Clinical Oncology | 2013 |
Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology | Association for Molecular Pathology | 2013 |
Evaluation of clinical validity and utility of actionable molecular diagnostic tests in adult oncology | Center for Medical Technology Policy | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology | College of American Pathologists,International Association for the Study of Lung Cancer, Association for Molecular Pathology | 2013 |
Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists | Dutch Society for Clinical Genetics | 2013 |
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? | Evaluation of Genomic Applications in Practice and Prevention | 2013 |
Canadian guideline on genetic screening for hereditary renal cell cancers | Kidney Cancer Research Network of Canada Genetics Initiative | 2013 |
EGFR Mutation Testing in Lung Cancer | Korean Cardiopulmonary Pathology Study Group | 2013 |
Clinical management of Lynch syndrome (HNPCC) | Mallorca Group | 2013 |
EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer | National Institute for Health and Care Excellence | 2013 |
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy | National Institute for Health and Care Excellence | 2013 |
Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer | National Institute for Health and Care Excellence | 2013 |
Familial breast cancer: summary of updated NICE guidance | National Institute for Health and Care Excellence | 2013 |
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat | National Institute for Health and Care Excellence | 2013 |
Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer | National Institute for Health and Care Excellence | 2013 |
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma | National Institute for Health and Care Excellence | 2013 |
Risk assessment and genetic counseling for hereditary breast and ovarian cancer | National Society of Genetic Counselors | 2013 |
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | St Gallen International Breast Cancer Conference (2013) Expert Panel | 2013 |
BRAF mutation testing algorithm for vemurafenib treatment in melanoma | UK Expert Panel | 2013 |
BRCA-related Cancer: Risk Assessment, Genetic Counseling and Genetic Testing | US Preventive Services Task Force | 2013 |
Breast Cancer: Medications for Risk Reduction | US Preventive Services Task Force | 2013 |
Lung Cancer: Screening | US Preventive Services Task Force | 2013 |
Levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers | Vienna Comprehensive Cancer Center Central Nervous System Unit, Neurooncology Taskforce | 2013 |
Management of patients with colon and rectal cancer | European Society for Medical Oncology | 2012 |
Biomarker testing in colorectal carcinoma | Spanish Society of Pathology, Spanish Society of Medical Oncology | 2012 |
UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumour | United Kingdom National External Quality Assessment Service | 2012 |
Screening for ovarian cancer | US Preventive Services Task Force | 2012 |
Can tumor gene expression profiling improve outcomes in patients with breast cancer? | Evaluation of Genomic Applications in Practice and Prevention | 2009 |
Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives | Evaluation of Genomic Applications in Practice and Prevention | 2009 |
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results | International Agency for Research on Cancer (IARC) Unclassified Genetic Variants Working Group | 2008 |
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? | Evaluation of Genomic Applications in Practice and Prevention | 2009 |
No hay comentarios:
Publicar un comentario